These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6384431)

  • 1. Regulation of lymphocyte activation by PGE2 in multiple sclerosis.
    DuBois JH; Cuzner ML
    J Neurol Sci; 1984 Aug; 65(2):211-9. PubMed ID: 6384431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin E inhibition of mitogen stimulation in patients with multiple sclerosis.
    Goodwin JS; Messner RP
    Prostaglandins; 1978 Feb; 15(2):281-6. PubMed ID: 635219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production.
    Walker C; Kristensen F; Bettens F; deWeck AL
    J Immunol; 1983 Apr; 130(4):1770-3. PubMed ID: 6601136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of prostaglandins on the proliferation of cultured human T lymphocytes.
    Maca RD
    Immunopharmacology; 1983 Dec; 6(4):267-77. PubMed ID: 6317610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of prostaglandin E and I analogues on lymphocyte stimulation.
    Kingston AE; Kay JE; Ivanyi J
    Int J Immunopharmacol; 1985; 7(1):57-64. PubMed ID: 3888868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin E2 inhibits the generation of phytohemagglutinin-activated killer activity in human peripheral blood lymphocytes.
    Yamashita N; Ito M; Suzuki H; Sugiyama E; Yokoyama A; Sato M; Yano S
    Anticancer Res; 1986; 6(5):1113-6. PubMed ID: 3492171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of prostaglandin E2 and thromboxane A2 synthesis and suppression of PHA-stimulated peripheral blood mononuclear leucocytes.
    Awara W; Hillier K; Jones D
    Immunology; 1986 Dec; 59(4):557-62. PubMed ID: 3468061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin-mediated inhibition of lymphokine secretion in normal individuals and patients with progressive systemic sclerosis (scleroderma, PSS).
    Kelly RH; Miller DH; Rodnan GP; Hagmann J
    Agents Actions; 1982 Oct; 12(4):471-7. PubMed ID: 6295107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of human B cell activation by prostaglandin E2. Suppression of the generation of immunoglobulin-secreting cells.
    Jelinek DF; Thompson PA; Lipsky PE
    J Clin Invest; 1985 Apr; 75(4):1339-49. PubMed ID: 3872889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression.
    Chouaib S; Welte K; Mertelsmann R; Dupont B
    J Immunol; 1985 Aug; 135(2):1172-9. PubMed ID: 2989362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressive effect of thymosin fraction 5 on proliferation of cultured human T lymphocytes.
    Wolf RE; Maca RD
    Immunopharmacology; 1986 Dec; 12(3):233-40. PubMed ID: 3493229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong suppression by mononuclear leukocytes from cord blood of human newborns on maternal leukocytes associated with differences in sensitivity to prostaglandin E2.
    Johnsen SA; Olofsson A; Gréen K; Olding LB
    Am J Reprod Immunol (1980); 1983; 4(1):45-9. PubMed ID: 6226208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin E2 inhibits human T-cell proliferation after crosslinking of the CD3-Ti complex by directly affecting T cells at an early step of the activation process.
    Vercammen C; Ceuppens JL
    Cell Immunol; 1987 Jan; 104(1):24-36. PubMed ID: 2948675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune dysfunction in primary biliary cirrhosis (PBC): I. Increased sensitivity of PHA stimulated lymphocyte cultures to indomethacin.
    Licastro F; Lenzi M; Chiricolo M; Davis LJ; Cassani F; Bianchi F; Franceschi C
    J Clin Lab Immunol; 1987 May; 23(1):19-23. PubMed ID: 3612758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of some prostaglandins and leukotrienes on lymphocytes, monocytes and their activity in vitro.
    Wasserman J; Hammarström S; Petrini B; Blomgren H; von Stedingk LV; Vedin I
    Int Arch Allergy Appl Immunol; 1987; 83(1):39-43. PubMed ID: 3032806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of anti-tuberculosis drugs on the production of prostaglandin E2 and on mononuclear leucocyte transformation.
    Zeis BM
    Chemotherapy; 1987; 33(3):204-10. PubMed ID: 3474108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human B cell responsiveness by prostaglandin E2.
    Simkin NJ; Jelinek DF; Lipsky PE
    J Immunol; 1987 Feb; 138(4):1074-81. PubMed ID: 3027169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential in vitro effects of etretinate and retinoic acid on the PHA and con A induced lymphocyte transformation, suppressor cell induction and leukocyte migration inhibitory factor (LMIF) production.
    Soppi E; Tertti R; Soppi AM; Toivanen A; Jansén CT
    Int J Immunopharmacol; 1982; 4(5):437-43. PubMed ID: 6215368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin sensitivity of the PHA-response of blood lymphocytes following radiation therapy for breast cancer.
    Blomgren H; Hammarström S; Wasserman J; Petrini B
    Radiother Oncol; 1986 Oct; 7(2):141-5. PubMed ID: 3466235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral administration of prostaglandin E2 to humans: effects on peripheral blood leukocyte function.
    Dore-Duffy P; Berube ML; Siok C; Zurier RB
    J Lab Clin Med; 1984 Aug; 104(2):283-91. PubMed ID: 6589334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.